'Realistic' to expect Ebola vaccine by 2015: WHO (Update)

Clinical trials of vaccines for the deadly Ebola virus should soon get underway and will likely be ready for widespread use by early next year, the World Health Organization said Saturday.

"I think it's realistic," Marie-Paule Kieny, assistant director-general of the UN health agency, told AFP.

There is currently no available cure or vaccine for Ebola, one of the deadliest viruses known to man, but Kieny said she expected a vaccine to be rushed through the trial process and become available by 2015.

Her colleague Jean-Marie Okwo Bele, who is vaccine chief at WHO, told French radio RFI earlier Saturday that British pharma giant GlaxoSmithKline appeared set to start clinical trials of a vaccine next month.

He also said he was optimistic about making the vaccine commercially available.

"Since this is an emergency, we can put emergency procedures in place ... so that we can have a vaccine available by 2015," he said.

Kieny acknowledged however that any vaccine rushed to market to help stem the epidemic, which has already claimed nearly 1,000 lives in west Africa, would not be tested as rigorously as other vaccines and drugs.

"Will it have been tested as well as other vaccines we put out in the field? No, absolutely not. That would be impossible," she said, a day after the WHO declared the epidemic an international health emergency.

The bar would likely be lowered to enable a vaccine to go to market after showing good results and safety in only a small number of people, as well as recording good data in primates, she said.

The WHO, Kieny said, was "engaging with quite a number of developers ... to see what we can do to help accelerate and facilitate the development."

It was especially important to speed up government authorisation of phase-one trials, which in Africa can often take months, she said.

Zmapp vaccine 'promising'

"We hope that because of the emergency this won't be treated as just any other drug or vaccine," she said.

Tests still need to be carried out in carefully controlled environments, to allow researchers to spot possible adverse effects and avoid wide distribution of unsafe drugs, she said.

"And if we just go blindly, in the end we won't know if (the vaccines or treatments) were useful or not," she added.

Several vaccines are being tested, and a treatment made by San Diego-based Mapp Biopharmaceutical, ZMapp, has shown promising results on monkeys and may have been effective in treating two Americans recently infected in Africa.

The use of the experimental drug has sparked an ethical debate about whether it is justifiable to use untested drugs, and if so, who should be treated.

Kieny, who will be hosting a WHO meeting on the issue on Monday, said ZMapp appeared "promising".

The problem, she said, was that there are no more than around a handful of the treatments available and it could prove difficult to scale up production.

"The good news is that it seems to work. The bad news is that it's not there for the time-being," she said.

Kieny, who headed WHO's vaccine division during the H1N1 swine flu pandemic in 2009, is acutely aware that helping rush a vaccine to market can cause controversy.

In 2009, WHO was accused of helping line the pockets of the pharmaceutical companies that profited from the swine flu vaccine.

"People might accuse us of playing with the industry, but all things considered, I would prefer to be criticised for a conflict of interest—which there definitely is not—than to be criticised for doing nothing," Kieny said.

add to favorites email to friend print save as pdf

Related Stories

WHO holds emergency Ebola meeting

Aug 06, 2014

The World Health Organization on Wednesday began a two-day emergency meeting on west Africa's Ebola epidemic, with the UN agency deciding whether to declare it an international crisis.

Recommended for you

Evidence-based recs issued for systemic care in psoriasis

6 hours ago

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

Bacteria in caramel apples kills at least four in US

6 hours ago

A listeria outbreak believed to originate from commercially packaged caramel apples has killed at least four people in the United States and sickened 28 people since November, officials said Friday.

Steroid-based treatment may answer needs of pediatric EoE patients

6 hours ago

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

Discovery of genes that predispose a severe form of COPD

9 hours ago

A study by Ramcés Falfán-Valencia, researcher at the National Institute of Respiratory Diseases (INER), found that the mestizo Mexican population has a number of variations in certain genes that predispose ...

On the environmental trail of food pathogens

10 hours ago

Tracking one of the deadliest food contamination organisms through produce farms and natural environments alike, Cornell microbiologists are showing how to use big datasets to predict where the next outbreak could start.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

TheGhostofOtto1923
1 / 5 (1) Aug 09, 2014
Scenario - terrorists kidnap infected and move them to neutral countries. A pool of infected martyrs is created who board planes for western airports. There they meet up with indigenous martyrs who are themselves infected and who proceed to spread contamination at bus and air terminals, sporting events, concerts, and so forth. The result?
https://www.youtu..._NVi-TC4
https://www.youtu...dt7z_WP8

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.